

Claims

1. An inhibitor for neuromuscular transmission comprising an M toxin (HA-negative substance) of type A botulinum toxin as an active ingredient.

2. A therapeutic agent for a disease caused by hypermyotonia comprising an M toxin (HA-negative substance) of type A botulinum toxin as an active ingredient.

3. The therapeutic agent according to claim 2, wherein the disease caused by hypermyotonia is strabismus, blepharospasm, hemifacial spasms, spasmodic torticollis, paralysis after cerebral apoplexy, infantile cerebral paralysis, spasmodic phonopathy, headache, lumbago, neck pain, back pain, stiff shoulder, muscular relaxation disorder accompanied by Parkinson's disease or multiple sclerosis, myofascial pain syndrome, masticatory spasm, chronic anal fissure, urinary inconsistency, grinding of teeth, facial myokymia, tic, topical dystonia or wrinkles.

4. The therapeutic agent according to claim 2, wherein molecular weight of the M toxin of type A botulinum toxin is 200,000 to 400,000.

5. The therapeutic agent according to claim 2, wherein the M toxin of type A botulinum toxin is produced by a strain of *Clostridium botulinum* type A 7I03-H, *Clostridium botulinum*

type A Chiba or *Clostridium botulinum* type A Kyoto-F.

6. The therapeutic agent according to any of claims 2 to 5, wherein the dosage form is an injection preparation.